STOCK TITAN
  1. Home
  2. News
  3. BLUE

bluebird bio, Inc. - BLUE STOCK NEWS

Welcome to our dedicated page for bluebird bio news (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on bluebird bio stock.

bluebird bio, Inc. (NASDAQ: BLUE) is a pioneering biotechnology company dedicated to researching, developing, and commercializing gene therapies aimed at treating severe genetic diseases. With a focus on transformative gene therapies, bluebird bio utilizes its proprietary lentiviral vector (LVV) gene addition platform to target a wide range of serious conditions. The company's mission is to develop potentially curative treatments by leveraging its integrated product platforms, which include gene therapy, cancer immunotherapy, and gene editing.

bluebird bio's operations are centered on a single segment dedicated to gene therapy innovation. Recent achievements highlight the company's commitment to advancing healthcare solutions. For instance, bluebird bio has formed strategic partnerships and collaborations aimed at accelerating the development of its gene therapies. These alliances provide critical support in bringing groundbreaking treatments to market.

Current projects at bluebird bio include clinical trials and research focused on severe genetic diseases. The company is exploring potential cures for conditions such as sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. Financially, bluebird bio has demonstrated robust growth and resilience, underpinned by strategic investments and a strong pipeline of products poised for commercialization.

The company's products are designed to address unmet medical needs, offering hope to patients who suffer from debilitating genetic disorders. bluebird bio's dedication extends beyond product development to include patient advocacy and health equity initiatives, ensuring broader access to innovative therapies.

In a recent notable event, Dr. Charlotte Jones-Burton was appointed to bluebird bio's board of directors, bringing a wealth of experience in clinical development and health equity advocacy. This addition signifies the company's ongoing commitment to enhancing its leadership team with experts who can drive strategic growth and innovation.

News

bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance

Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) reported fourth quarter and annual financial results for 2023, highlighting a $175 million term loan facility with Hercules Capital extending cash runway through Q1 2026. The Company anticipates 85 to 105 patient starts in 2024 across its gene therapy portfolio, with a focus on LYFGENIA for sickle cell disease. Recent commercial progress includes government outcomes-based agreement with Michigan Medicaid and activation of 62 Qualified Treatment Centers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
-
News

bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call

Rhea-AI Summary
bluebird bio, Inc. (BLUE) will host a conference call on March 26, 2024, to discuss Q4 and 2023 annual results and business updates. The call can be accessed via telephone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
conferences
-
News

bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital

Rhea-AI Summary
bluebird bio secures a $175 million term loan facility with Hercules Capital, extending its cash runway for up to 24 months. The company draws the first tranche of $75 million with the potential to access an additional $50 million based on commercial milestones. This funding aims to support the commercial launches of its FDA-approved gene therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
News

bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy

Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) announces its first Medicaid outcomes-based agreement for LYFGENIA gene therapy with Michigan, aiming to provide timely access to sickle cell disease patients. The agreement reflects the company's commitment to equitable access and value-based contracting approaches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.33%
Tags
none
-
News

bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook

Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) announced updates at the 42nd Annual J.P. Morgan Healthcare conference, including commercial launch progress, 2024 program milestones, and financial outlook. LYFGENIA is expected to have 85 to 105 patient starts in 2024, with the first patient start in Q1 2024. The company's cash, cash equivalents, and marketable securities are expected to fund current operations into Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.52%
Tags
none
-
News

bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) CEO to Present Corporate Update at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
conferences
News

bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) announced the pricing of its underwritten public offering of 83,333,333 shares of its common stock at a public offering price of $1.50 per share, with expected gross proceeds of $125 million. The company plans to use the net proceeds to support commercialization and manufacturing for its approved gene therapies and for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.68%
Tags
offering
-
News

bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) has announced a public offering of $150,000,000 of its common stock, with an option for underwriters to purchase an additional $22,500,000. The offering will support commercialization and manufacturing of its three approved gene therapies, ZYNTEGLO, SKYSONA, and LYFGENIA, as well as fund working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.33%
Tags
offering
-
News

Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Rhea-AI Summary
bluebird bio inc. (NASDAQ: BLUE) presented updated data at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, showing sustained transfusion independence and improvements in iron management in patients with transfusion-dependent beta-thalassemia treated with beti-cel. The data demonstrated durable transfusion independence and a continued positive safety profile in patients through up to nine years of follow-up, reflecting beti-cel's potential as a curative therapy. A total of 63 patients across four clinical studies received beti-cel, with 90.2% of patients in the Phase 3 studies achieving transfusion independence. The safety results following beti-cel treatment largely reflected known side effects, with 19% of patients experiencing beti-cel-related adverse events. Iron management outcomes showed that 69% of patients were able to stop chelation therapy, demonstrating reduced iron management burden in those patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events

Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) announced new and updated efficacy, safety, and health-related quality of life data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease. The data presented at ASH show that lovo-cel has the potential to address the underlying cause of sickle cell disease and provide robust clinical benefits for patients, with 94% complete resolution of sVOEs and 88% complete resolution of VOEs achieved in evaluable patients. The therapy has shown a durable impact on the underlying cause of sickle cell disease, with reductions in VOE frequency and severity, and significant improvements in hemolysis markers and health-related quality of life measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of bluebird bio (BLUE)?

The current stock price of bluebird bio (BLUE) is $0.3626 as of November 14, 2024.

What is the market cap of bluebird bio (BLUE)?

The market cap of bluebird bio (BLUE) is approximately 80.7M.

What is bluebird bio, Inc.?

bluebird bio, Inc. is a biotechnology company focused on developing gene therapies for severe genetic diseases using its proprietary lentiviral vector platform.

What does bluebird bio specialize in?

bluebird bio specializes in gene therapy, cancer immunotherapy, and gene editing, aiming to provide curative treatments for serious genetic disorders.

What recent achievements has bluebird bio accomplished?

Recent achievements include strategic partnerships and the appointment of Dr. Charlotte Jones-Burton to the board, enhancing clinical development and health equity efforts.

What are some of bluebird bio's current projects?

Current projects include clinical trials for conditions such as sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.

What is bluebird bio's financial condition?

bluebird bio has shown strong financial performance, supported by strategic investments and a robust pipeline of transformative gene therapy products.

What products does bluebird bio offer?

bluebird bio offers gene therapies designed to treat severe genetic diseases, addressing unmet medical needs and providing potential cures.

Who are bluebird bio's key partners?

bluebird bio partners with various organizations and experts to advance its gene therapy developments, enhancing its ability to bring innovative treatments to market.

How does bluebird bio ensure health equity?

bluebird bio focuses on patient advocacy and health equity initiatives to ensure broader access to its groundbreaking therapies.

Who is Dr. Charlotte Jones-Burton?

Dr. Charlotte Jones-Burton is a new board member of bluebird bio with extensive experience in clinical development and advancing health equity in the biopharmaceutical industry.

What is the significance of bluebird bio's gene therapy platform?

bluebird bio's lentiviral vector gene addition platform is significant for its potential to develop curative therapies for a wide range of severe genetic diseases.

Stock BLUE logo
bluebird bio, Inc.

Nasdaq:BLUE

BLUE Rankings

#4540 Ranked by Market Cap
N/A Ranked by Dividends

BLUE Stock Data

80.75M
193.91M
0.63%
43.76%
25.48%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOMERVILLE